Gilead Sciences has released detailed results from two pivotal clinical trials, Artistry-1 and Artistry-2, evaluating a novel investigational combination tablet known as BIC/LEN. This therapy fuses bictegravir (a core component of Biktarvy) with lenacapavir (a first-in-class capsid inhibitor), aiming to provide a simplified option for individuals currently on complex multi-pill HIV treatment regimens.
The Artistry-1 study focused on long-term survivors who have managed HIV for a median of 28 years and were taking between 2 and 11 pills daily due to drug resistance or tolerance issues. At week 48, switching to the single-tablet BIC/LEN proved non-inferior in maintaining viral suppression compared to complex multi-tablet programs. Furthermore, participants experienced improved fasting lipid levels and a significant increase in treatment satisfaction scores.
Simultaneously, the Artistry-2 trial compared BIC/LEN against Biktarvy, the current global standard of care. The data demonstrated that the new combination was as effective as Biktarvy in suppressing the virus, positioning it as a viable alternative for patients seeking streamlined therapy without compromising efficacy or safety.
BIC/LEN is expected to address the unmet needs of approximately 5% of the HIV population in the U.S. currently struggling with burdensome regimens. This launch is a key component of Gilead’s plan to introduce seven new HIV products over the next seven years, with analysts predicting a potential market debut in 2027.